Key stats
About INVESTO NUCLCI
Home page
Inception date
Dec 15, 2021
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Capitalizes
Primary advisor
Investo Gestão de Recursos Ltda.
ISIN
BRNUCLCTF002
The BTEK11 ETF is an index fund listed on B3 that replicates in Brazil the well-known XBI ETF (S&P Biotechnology Select Industry Index ) , a leading biotechnology fund listed on the New York Stock Exchange.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
NUCL11 assets under management is 7.23 M BRL. It's fallen 3.19% over the last month.
NUCL11 fund flows account for 6.15 M BRL (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
No, NUCL11 doesn't pay dividends to its holders.
NUCL11 shares are issued by Investo Gestão de Recursos Ltda. under the brand Investo. The ETF was launched on Dec 15, 2021, and its management style is Passive.
NUCL11 follows the S&P Biotechnology Select Industry. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
NUCL11 price has risen by 15.81% over the last month, and its yearly performance shows a −0.20% decrease. See more dynamics on NUCL11 price chart.
NAV returns, another gauge of an ETF dynamics, have fallen by −4.30% over the last month, showed a −18.37% decrease in three-month performance and has decreased by −9.35% in a year.
NAV returns, another gauge of an ETF dynamics, have fallen by −4.30% over the last month, showed a −18.37% decrease in three-month performance and has decreased by −9.35% in a year.
NUCL11 trades at a premium (0.23%) meaning the ETF is trading at a higher price than the calculated NAV.